The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: A prospective sequential nonrandomized study

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2713-2718

  Stemmer, Salomon M ^a   Rizel, Shulamith ^a   Hardan, Izhar ^a   Adamo, Adamous ^a   Neumann, Avivit ^a   Goffman, Jana ^a   Brenner, Harold J ^a   Pfeffer, M Raphael ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; IRRADIATION; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADULT; BREAST TUMOR; CARCINOMA; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; MASTECTOMY; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIOTHERAPY; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHATIC IRRADIATION; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041629489     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.096     Document Type: Article

References (28)

1. Marks LB, Halperin EC, Prosnitz LR, et al: Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys 23:1021-1026, 1992
2. Recht A, Edge SB, Solin LJ, et al: Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569, 2001
3. Ragaz J, Jackson SM, Le N, et al: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337:956-962, 1997
4. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
5. Stemmer SM, Pfeffer MR, Rizel S, et al: Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma. Cancer 91:1983-1991, 2001
6. Peters WP, Rosner G, Vredenburgh J, et al: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 2)
7. Rodenhuis S, Bontenbal M, Beex LVAM, et al: Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc Am Soc Clin Oncol 19:74a, 2000 (abstr 286)
8. Zander AR, Kröger W, Kröger N, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support (HSCS) vs. standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. Proc Am Soc Clin Oncol 21:xa, 2002 (abstr 1658)
9. Antman KH: Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer. J Natl Cancer Inst Monogr 30:114-116, 2001
10. Gianni L: High-dose chemotherapy for breast cancer: Any use for it? Ann Oncol 13:650-652, 2002
11. Nikcevich DA, Vredenburgh JJ, Broadwater G, et al: Ten year follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Proc Am Soc Clin Oncol 22:415a, 2002 (abstr 1657)
12. Fleming ID, Cooper JS, Henson DE, et al (eds): American Joint Committee on Cancer Staging Manual (ed 5). Philadelphia, Lippincott Raven, 1997
13. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
14. Handley RS: A surgeon's view of the spread of breast cancer. Cancer 24:1232-1239, 1969
15. Kuske RR: Adjuvant chest wall and nodal irradiation: Maximize cure, minimize late cardiac toxicity. J Clin Oncol 16:2579-2582, 1998
16. Freedman GM, Fowble BL, Nicolaou N, et al: Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys 46:805-814, 200
17. Fisher BJ, Perera FE, Cooke AL, et al: Long-term follow up of axillary node positive breast cancer patients receiving adjuvant systemic therapy alone: Patterns of recurrence. Int J Radiat Oncol Biol Phys 38:541-550, 1997
18. Cuzick J, Stewart H, Ritqvist LE, et al: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994
19. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355:1757-1770, 200
20. Obedian E, Haffty BG: Internal mammary nodal irradiation in conservatively-managed breast cancer patients: Is there a benefit? Int J Radiat Oncol Biol Phys 44:997-1003, 1999
21. Montague ED, Fletcher GH: The curative value of irradiation in the treatment of nondisseminated breast cancer. Cancer 46:995-998, 1980 (suppl 4)
22. Fletcher GH, McNeese MD, Oswald MJ: Long-range results for breast cancer patients treated by radical mastectomy and postoperative radiation without adjuvant chemotherapy: An update. Int J Radiat Oncol Biol Phys 17:11-14, 1989
23. Chahbazian CM, del Regato JA, Wilson JF: Postoperative radiation therapy for "early" carcinoma of the breast. Cancer 42:1126-1128, 1978
24. Zucali R, Mariani L, Marubini E, et al: Early breast cancer Evaluation of the prognostic role of the site of the primary tumor. J Clin Oncol 16:1363-1366, 1998
25. Roseman JM, James AG: The significance of the internal mammary lymph nodes in medially located breast cancer. Cancer 50:1426-1429, 1982
26. Le MG, Arriagada R, de Vathaire F, et al: Can internal mammary chain treatment decrease the risk of death for patients with medial breast cancers and positive axillary lymph nodes? Cancer 66:2313-2318, 199
27. Kaija H, Maunu P: Tangential breast irradiation with or without internal mammary chain irradiation: Results of a randomized trial. Radiother Oncol 36:172-176, 1995
28. Lievens Y, Poortmans P, Van den Bogaert W: A glance on quality assurance in EORTC study 22922 evaluating techniques for internal mammary and medial supraclavicular lymph node chain irradiation in breast cancer. Radiother Oncol 60:257-265, 2001